Genomic signatures define three subtypes of resected EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Release date:
2021-10-22
Description:
The ADJUVANT study reported comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival (DFS) of EGFR-mutant resected stage II-IIIA non-small-cell lung cancer (NSCLC). However, inconsistent clinical benefits have necessitated precise genetic categorization for adjuvant guidance.
For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.
You need to install the Aspera Connect plugin before uploading your files. If you dont have Aspera Connect plugin installed in your computer, please Download Aspera Connectand install it first.
[path/to/ascp]: Microsoft Windows: C:\Program Files\Aspera\Aspera Connect\bin\ascp.exe or
c:\users\[username]\AppData\Local\Programs\Aspera\Aspera Connect\bin\ascp.exe
Mac OS X: /Applications/Aspera/Connect.app/Contents/Resources/ascp (for admin's installation) or
/Users/[username]/Applications/Aspera/Connect.app/Contents/Resources/ascp (for non-admin's installation)
Linux: /opt/aspera/bin/ascp or
/home/[username]/aspera/connect/bin/ascp
[path/to/key/file] must be an absolute path, e.g.: /home/keys/aspera.openssh
[path/to/folder/containing/files] needs to specify the local folder that contains all the files to upload.
HRA001462.xlsx